192 related articles for article (PubMed ID: 16291008)
1. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Davidson MH
Am J Cardiol; 2005 Nov; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008
[TBL] [Abstract][Full Text] [Related]
2. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Polonsky TS; Davidson MH
Am J Cardiol; 2008 Apr; 101(8A):27B-35B. PubMed ID: 18375238
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
7. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
8. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
Ballantyne CM
Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
[TBL] [Abstract][Full Text] [Related]
9. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Sudhop T; von Bergmann K
MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
11. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Hobbs FD
Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
13. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
van der Harst P; Wagenaar LJ; Buikema H; Voors AA; Plokker HW; Morshuis WJ; Six AJ; Boonstra PW; Nickenig G; Wassmann S; van Veldhuisen DJ; van Gilst WH
Am J Cardiol; 2005 Nov; 96(10):1361-4. PubMed ID: 16275178
[TBL] [Abstract][Full Text] [Related]
14. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
[No Abstract] [Full Text] [Related]
15. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Kastelein JJ
Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
[TBL] [Abstract][Full Text] [Related]
16. [Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
MMW Fortschr Med; 2001 Apr; 143(14):44. PubMed ID: 11340911
[No Abstract] [Full Text] [Related]
17. Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Unnikrishnan R; Das R; Jaydip R; Sudhakaran C; Mohan V
J Assoc Physicians India; 2009 Feb; 57():180-1. PubMed ID: 19582991
[TBL] [Abstract][Full Text] [Related]
18. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
19. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
20. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
